Slide 1: May 2018 Presentation
HMiKAL May 2018 Presentation
Slide 2: Safe Harbor
Safe Harbor H iy K. A zk This presentation and the accompanying slides (the “Presentation”), which have been prepared by Hikal Limited (the “Company’”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any s
Slide 3: Company Overview
Company Overview • • • • • © Hikal Limited
Slide 4: Hybrid Business Model
Hybrid Business Model • • • • • • • • • © Hikal Limited
Slide 5: Evolution
Evolution Commenced operations with a plant in Mahad. Established R&D center in Pune to focus on R&D and Second Plant commissioned augment pharmaceuticals in Taloja along with Merck, and crop protection USA processes Diversified into pharmaceuticals business by acquiring Panoli plant from Novartis (
Slide 6: Timeline
x Timeline H ] K. A zk 1988 _ Hikal is incorporated 1991 First Manufacturing site at Mahad begins operations - Signed a long term supply agreement with Hoescht India 1995 _ Signed a long term manufacturing and supply agreement with Merck, U.S., for a large volume Agvet Active Ingredient 1997 Manufac
Slide 7: Global Regulatory Compliances
Global Regulatory Compliances © Hikal Limited
Slide 8: Regulatory Milestones
Regulatory Milestones © Hikal Limited
Slide 9: Board of Directors
Board of Directors © Hikal Limited
Slide 10: Management Team
Management Team © Hikal Limited
Slide 11: Scientific Advisory Board
Scientific Advisory Board 01 © Hikal Limited
Slide 12: Focused Strategy
Focused Strategy • • Relationships • • © Hikal Limited
Slide 13: Value Chain
Value Chain H iy K. A zk Expertise in Custom Synthesis and Contract Research with capabilities scaling up from Gram to Kilo and Ton level of Production Lead molecule Launch identified . On patent Off patent Discovery research Pre launch growing mature Off patent Discovery Development Full scale Manu
Slide 14: Contract Development & Manufacturing
Contract Development & Manufacturing © Hikal Limited
Slide 15: Hikal – Locations
Hikal – Locations © Hikal Limited
Slide 16: Manufacturing Capabilities
Manufacturing Capabilities 2009 2003 2001 2000 1997 1991 © Hikal Limited
Slide 17: Pharmaceuticals
Pharmaceuticals • • • • © Hikal Limited
Slide 18: Pharmaceuticals – Facility Overview
Pharmaceuticals – Facility Overview • • • • • • • • • • • • • © Hikal Limited
Slide 19: Existing Contracts
Existing Contracts • • • • • • • © Hikal Limited
Slide 20: Future Strategy
Future Strategy • • • • • • • • • • • • • • • © Hikal Limited
Slide 21: Crop Protection
Crop Protection • • • • • © Hikal Limited
Slide 22: Crop Protection – Facility Overview
Crop Protection – Facility Overview • • • • • • • • © Hikal Limited
Slide 23: Key Relationships
Key Relationships © Hikal Limited
Slide 24: Future Strategy
Future Strategy • • • • • • • • © Hikal Limited
Slide 25: Research & Development Update
Research & Development Update 500 6% R&D (in mn) As % to Sales 450 5% • 400 5% 350 4% 4% 4% 4% 300 4% 3% • 250 3% 2% 440 200 345 347 362 2% 150 2% 318 311 100 1% • 50 102 133 0 0% FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 • • • • © Hikal Limited
Slide 26: Our R & D Efforts
Our R & D Efforts • • • • • • • • • • © Hikal Limited
Slide 27: R&D – Facility Overview
R&D – Facility Overview • ▪ • ▪ ▪ ▪ ▪ • ▪ ▪ ▪ © Hikal Limited
Slide 28: Research & Development Expertise
Research & Development Expertise ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ © Hikal Limited
Slide 29: Intellectual Capital
Intellectual Capital © Hikal Limited
Slide 30: Animal Health – A Natural Progression
Animal Health – A Natural Progression © Hikal Limited
Slide 31: Key Strengths
Key Strengths New Experienced Management Team Regulatory Compliances Strong Research & Development Established Relations with Clients © Hikal Limited
Slide 32: Growth Drivers
Growth Drivers ▪ ▪ ▪ ▪ ▪ ▪ © Hikal Limited
Slide 33: Financials
Financials
Slide 34: Operational Highlights
Operational Highlights 13,001 +11% 2,418 +15% 10,340 9,257 1,972 8,292 8,719 1,884 1,910 1,883 1,841 1,809 1,790 6,942 6,604 1,326 1,283 5,360 4,780 4,935 830 3,120 FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 © Hikal Limited
Slide 35: Operational Highlights
Operational Highlights 7,528 5,473 +17% 6,107 5,691 5,375 +13% 4,233 4,754 3,538 3,565 4,477 3,344 3,570 3,716 2,888 3,210 2,465 2,759 2,021 1,791 1,734 1,580 1,540 FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 © Hikal Limited
Slide 36: Capital Expenditure
Capital Expenditure Rs. 1,857 1,774 1,750 1,635 1,546 1,410 1,367 1,256 1,132 1,029 1,023 757 701 613 645 519 521 529 509 457 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 © Hikal Limited
Slide 37: Standalone Profit & Loss – Quarterly
Standalone Profit & Loss – Quarterly © Hikal Limited
Slide 38: Standalone Profit & Loss - Annual
Standalone Profit & Loss - Annual © Hikal Limited
Slide 39: Standalone Balance Sheet
Standalone Balance Sheet © Hikal Limited
Slide 40: Annual Dividend Payout
Annual Dividend Payout 26% 26% 21% 19% 14% 24% 24% 18% 19% 9.40 8.55 7.77 7.32 6.58 5.39 4.92 5.03 3.07 1.60 1.20 1.20 0.90 1.00 1.00 1.20 1.20 0.50 FY10 FY11 FY12 FY13 FY14* FY15 FY16 FY17 FY18 EPS DPS ▪ ▪ © Hikal Limited
Slide 41: Contact Us
Contact Us HIKAL Company : Hikal Limited CIN: L24200MH1988PTC048028 Mr. Sham V. Wahalekar sham_wahalekar@hikal.com www.hikal.com HiKAL SG A Strategic Growth Advisors Investor Relations Advisors : Strategic Growth Advisors Pvt. Ltd. CIN: U74140MH2010PTC204285 Ms. Payal Dave / Mr. Jigar Kavaiya +91-98
Slide 42: HiKAL
HiKAL